Elevidys

sarepta building
Favicon Fierce Pharma

Sarepta CEO to retire, citing 'shocking and ironic twist of fate'

Ingram’s departure comes at a crossroads for Sarepta, as the unwavering conviction that defined his tenure faces major commercial uncertainty.
Angus Liu Feb 26, 2026 11:30am
calendar
Favicon Fierce Pharma

Sarepta extends $700M debt to 2030 amid Elevidys uncertainty

Aug 21, 2025 10:52am
FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

Aug 9, 2025 12:22pm
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am
sarepta building
Favicon Fierce Pharma

FDA backtracks on Sarepta's gene therapy Elevidys in DMD

Jul 28, 2025 6:02pm